poisar

Stocks · News reference

UBS Maintains Buy on Encompass Health, Raises Price Target to $155

Aug 7, 2026, 11:37 PMBenzinga Newsdesk

UBS analyst A.J. Rice maintains Encompass Health (NYSE:EHC) with a Buy and raises the price target from $150 to $155.

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

EHC
Source
benzinga
Observed
Aug 7, 2026, 11:37 PM
Checked
Aug 7, 2026, 11:37 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. Aug 16, 2026, 7:13 PMJonathan Ponciano

    What Three Encompass Health Insiders Selling Signals After a Rate Increase

    Encompass Health's EVP and general counsel John Patrick Darby sold 8,906 shares (11% of his direct holdings) for $1.1 million on August 10, 2026, following strong earnings and a stock rally. The sale comes after the company raised guidance due to a favorable 2.3% Medicare rate increase for inpatient rehabilitation services starting in October. While multiple insiders trimmed positions after the earnings-driven rally, the article emphasizes that Medicare reimbursement rates are the key factor for investors to monitor, as they directly impact the company's pricing and profitability.

    Read original at the-motley-fool
    EHC
  3. Aug 16, 2026, 7:05 PMJonathan Ponciano

    Encompass Health's CFO Trimmed His Stake as Shares Jumped After Earnings. Here's What to Know

    Encompass Health's CFO Douglas Coltharp sold 18,869 shares worth $2.4 million on August 10, reducing his direct stake by 27% but maintaining a total beneficial ownership of 241,000 shares valued at $30.4 million. The sale occurred the same day as the CEO's larger stake reduction, following strong Q2 earnings that included 10% revenue growth, raised full-year guidance, and increased dividend/buyback authorization.

    Read original at the-motley-fool
    EHC